E2F1 and prostate cancer: Evaluation of VCaP prostate cancer cell line–derived mouse xenograft tumors after 5 days of NXP800 treatment by RNA-seq demonstrated significant de-enrichment of Hallmark E2F Targets together with significantly decreased “activating” E2F (E2F1–3) RNA levels when compared with vehicle controls (Fig. 6C and D).